Tags : Research

Domain Therapeutics Signs Research and License Agreement with Boehringer Ingelheim

Shots: Domain to receive upfront, milestones, and royalties on sales from Boehringer Ingelheim The focus of the agreement is to discover & develop GPCRs, using Domain’s DTect-All and bioSens-All technology to characterize compounds for Neuropsychiatric Diseases GPCRs are receptors present in CNS, activates by binding with stimulus or ligand and regulates the functions of brain […]Read More

Gilead Signs Global Research Collaboration with Tango to Develop &

Shots: Tango to get $50M upfront plus $1.7B as preclinical fees and milestone payments in addition to royalties in response Gilead has option to license WW rights to five targets developed from Tango’s genomics-based discovery platform Additionally, Tango has option to co-develop and co-retain two program from the above five targets in the US & […]Read More

Lilly Signs a Global Research and License Collaboration with Dicerna

Shots: Dicerna will receive $100M upfront plus ~$350M as development and commercialization milestones with tiered royalties and equity investment of $100M Lilly will get hold of Dicerna’s GalXC RNAi technology as well as development and commercialization rights to new developed drugs in fields of cardio-metabolic diseases, neurodegeneration and pain Dicerna’s GalXC RNAi technology is an […]Read More

Kite and HiFiBio Signs a Research & License Agreement for

Shots: The collaboration is focused on developing technology for neoantigen-reactive T cell receptors (TCRs) to treat cancers, including solid tumor HiFiBio to get an upfront $10M with additional milestones payments and Kite will hold an exclusive option to license HiFiBiO’s single cell technology platform HiFiBio Therapeutics is focused on activating human immune system to fight […]Read More